{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:56:16Z","timestamp":1789775776612,"version":"4.0.1"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Tumor development is frequently accompanied by abnormal expression of multiple genomic genes, which can be broadly viewed as decreased expression of tumor suppressor genes and upregulated expression of oncogenes. In this process, epigenetic regulation plays an essential role in the regulation of gene expression without alteration of DNA or RNA sequence, including DNA methylation, RNA methylation, histone modifications and non-coding RNAs. Therefore, drugs developed for the above epigenetic modulation have entered clinical use or preclinical and clinical research stages, contributing to the development of antitumor drugs greatly. Despite the efficacy of epigenetic drugs in hematologic caners, their therapeutic effects in solid tumors have been less favorable. A growing body of research suggests that epigenetic drugs can be applied in combination with other therapies to increase efficacy and overcome tumor resistance. In this review, the progress of epigenetics in tumor progression and oncology drug development is systematically summarized, as well as its synergy with other oncology therapies. The future directions of epigenetic drug development are described in detail.<\/jats:p>","DOI":"10.3389\/fgene.2022.1085391","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T04:43:17Z","timestamp":1672807397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Recent advances in epigenetic anticancer therapeutics and future perspectives"],"prefix":"10.3389","volume":"13","author":[{"given":"Liwen","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","article-title":"Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials","volume":"59","author":"Albrecht","year":"2016","journal-title":"J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/07357907.2012.675381","article-title":"MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma","volume":"30","author":"Amato","year":"2012","journal-title":"Cancer Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2017.99","article-title":"Non-coding RNA networks in cancer","volume":"18","author":"Anastasiadou","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1615\/critrevoncog.2014012378","article-title":"Drug combinations with HDAC inhibitors in antitumor therapy","volume":"20","author":"Arrighetti","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"B5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1159\/000441849","article-title":"Cytotoxic effects of valproic acid on neuroendocrine tumour cells","volume":"103","author":"Arvidsson","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1158\/1541-7786.MCR-15-0472","article-title":"BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer","volume":"14","author":"Asangani","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/13543784.2019.1583742","article-title":"RX-3117 (fluorocyclopentenyl cytosine): A novel specific antimetabolite for selective cancer treatment","volume":"28","author":"Balboni","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108815","DOI":"10.1016\/j.jnutbio.2021.108815","article-title":"Pterostilbene leads to DNMT3B-mediated DNA methylation and silencing of OCT1-targeted oncogenes in breast cancer cells","volume":"98","author":"Beetch","year":"2021","journal-title":"J. Nutr. Biochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: A dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jsbmb.2017.08.010","article-title":"Efficacy of hybrid vitamin D receptor agonist\/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer","volume":"177","author":"Bijian","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature05913","article-title":"Perceptions of epigenetics","volume":"447","author":"Bird","year":"2007","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjh.17076","article-title":"A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients","volume":"191","author":"Bird","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2016.02.043","article-title":"Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - the SHELTER study","volume":"65","author":"Bitzer","year":"2016","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","article-title":"Histone lysine methylation dynamics: Establishment, regulation, and biological impact","volume":"48","author":"Black","year":"2012","journal-title":"Mol. Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.3390\/cancers13143606","article-title":"Functional roles of bromodomain proteins in cancer","volume":"13","author":"Boyson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1535-7163.MCT-09-1202","article-title":"Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy","volume":"9","author":"Brueckner","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"152900","DOI":"10.1016\/j.phymed.2019.152900","article-title":"Repurposing natural products as novel HDAC inhibitors by comparative analysis of gene expression profiles","volume":"59","author":"Byun","year":"2019","journal-title":"Phytomedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/nar\/gky1230","article-title":"FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer","volume":"47","author":"Chae","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-12-387685-0.00007-X","article-title":"The DNMT3 family of mammalian de novo DNA methyltransferases","volume":"101","author":"Chedin","year":"2011","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2068517","DOI":"10.1155\/2018\/2068517","article-title":"SARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy","volume":"2018","author":"Choy","year":"2018","journal-title":"Sarcoma"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cncr.29175","article-title":"Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma","volume":"121","author":"Choy","year":"2015","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1634\/theoncologist.2015-0165","article-title":"Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"20","author":"Cogle","year":"2015","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1200\/JCO.21.00944","article-title":"E2112: Randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group","volume":"39","author":"Connolly","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.molcel.2019.08.026","article-title":"Lysine methylation regulators moonlighting outside the epigenome","volume":"75","author":"Cornett","year":"2019","journal-title":"Mol. Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Coude","year":"2015","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"14197","DOI":"10.1021\/acs.jmedchem.0c00919","article-title":"Tranylcypromine based lysine-specific demethylase 1 inhibitor: Summary and perspective","volume":"63","author":"Dai","year":"2020","journal-title":"J. Med. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/15257770.2011.652330","article-title":"Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine","volume":"31","author":"Damaraju","year":"2012","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4103\/jcrt.JCRT_390_20","article-title":"Evaluation of promoter hypermethylation of tumor suppressor gene BRCA1 in epithelial ovarian cancer","volume":"18","author":"Das","year":"2022","journal-title":"J. Cancer Res. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1073\/pnas.1919507117","article-title":"MYC protein stability is negatively regulated by BRD4","volume":"117","author":"Devaiah","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/Cedazuridine: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: A novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: Advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13059-020-02201-1","article-title":"Simultaneous epigenetic perturbation and genome imaging reveal distinct roles of H3K9me3 in chromatin architecture and transcription","volume":"21","author":"Feng","year":"2020","journal-title":"Genome Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","article-title":"Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer","volume":"25","author":"Ferrari","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"103399","DOI":"10.1016\/j.critrevonc.2021.103399","article-title":"DNA methylation in oral squamous cell carcinoma: From its role in carcinogenesis to potential inhibitor drugs","volume":"164","author":"Flausino","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","article-title":"A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma","volume":"89","author":"Galli","year":"2010","journal-title":"Ann. Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e55481","DOI":"10.1371\/journal.pone.0055481","article-title":"A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41419-017-0040-5","article-title":"The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis","volume":"9","author":"Gao","year":"2018","journal-title":"Cell Death Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: Results of a phase 2 study","volume":"3","author":"Garcia-Manero","year":"2019","journal-title":"Blood Adv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(19)30029-8","article-title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: Phase 2 results from a multicentre, open-label, randomised, phase 1\/2 trial","volume":"6","author":"Garcia-Manero","year":"2019","journal-title":"Lancet Haematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1016\/j.ejmech.2009.07.025","article-title":"Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of the PCAF histone acetyltransferase","volume":"44","author":"Ghizzoni","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejmech.2011.11.001","article-title":"6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site","volume":"47","author":"Ghizzoni","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e98176","DOI":"10.1371\/journal.pone.0098176","article-title":"3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells","volume":"9","author":"Girard","year":"2014","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.18632\/oncotarget.1909","article-title":"Anti-neoplastic properties of hydralazine in prostate cancer","volume":"5","author":"Graca","year":"2014","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/1476-4598-9-305","article-title":"Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation","volume":"9","author":"Gravina","year":"2010","journal-title":"Mol. Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.oraloncology.2012.05.024","article-title":"Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent\/metastatic head and neck cancer","volume":"48","author":"Haigentz","year":"2012","journal-title":"Oral Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","article-title":"Functions of N6-methyladenosine and its role in cancer","volume":"18","author":"He","year":"2019","journal-title":"Mol. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"B56","unstructured":"ClinicalTrials.gov. NCT055841112022\n            HolzJ.\n          2022"},{"key":"B57","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccell.2019.03.006","article-title":"Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia","volume":"35","author":"Huang","year":"2019","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/nar\/gku1276","article-title":"Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5","volume":"43","author":"Huang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"194567","DOI":"10.1016\/j.bbagrm.2020.194567","article-title":"Understanding the interplay between CpG island-associated gene promoters and H3K4 methylation","volume":"1863","author":"Hughes","year":"2020","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"B60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cytogfr.2012.08.002","article-title":"The HAT\/HDAC interplay: Multilevel control of STAT signaling","volume":"23","author":"Icardi","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/0008-5472.CAN-12-2730","article-title":"Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment","volume":"73","author":"Isaacs","year":"2013","journal-title":"Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"111107","DOI":"10.1016\/j.celrep.2022.111107","article-title":"Alphaherpesvirus US3 protein-mediated inhibition of the m6A mRNA methyltransferase complex","volume":"40","author":"Jansens","year":"2022","journal-title":"Cell Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7150\/thno.46360","article-title":"Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"key":"B64","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1038\/s41467-022-34815-3","article-title":"DNA methylation-based classification of sinonasal tumors","volume":"13","author":"Jurmeister","year":"2022","journal-title":"Nat. Commun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"104357","DOI":"10.1016\/j.ebiom.2022.104357","article-title":"Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma","volume":"86","author":"Ka-Yue Chow","year":"2022","journal-title":"EBioMedicine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-11-1021","article-title":"Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers","volume":"71","author":"Kogo","year":"2011","journal-title":"Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3892\/ol.2020.12014","article-title":"The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells","volume":"20","author":"Kojima","year":"2020","journal-title":"Oncol. Lett."},{"key":"B69","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/s1074-7613(01)00227-8","article-title":"A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival","volume":"15","author":"Lee","year":"2001","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-0459","article-title":"BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC","volume":"78","author":"Leonard","year":"2018","journal-title":"Cancer Res."},{"key":"B72","first-page":"240","article-title":"Histone demethylase GASC1 inhibitor targeted GASC1 gene to inhibit the malignant transformation of esophageal cancer through the NOTCH-MAPK signaling pathway","volume":"52","author":"Li","year":"2022","journal-title":"Ann. Clin. Lab. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"6650781","DOI":"10.1155\/2021\/6650781","article-title":"Histone methyltransferase G9a promotes the development of renal cancer through epigenetic silencing of tumor suppressor gene SPINK5","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"7186","DOI":"10.1021\/acs.jmedchem.0c00456","article-title":"Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/annonc\/mdy119","article-title":"Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification","volume":"29","author":"Liu","year":"2018","journal-title":"Ann. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/aps.2016.64","article-title":"Histone lysine methyltransferases as anti-cancer targets for drug discovery","volume":"37","author":"Liu","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"B77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3727\/096504005775082066","article-title":"In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines","volume":"15","author":"Loprevite","year":"2005","journal-title":"Oncol. Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3892\/or.10.4.935","article-title":"Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival","volume":"10","author":"Maeda","year":"2003","journal-title":"Oncol. Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2016.117","article-title":"Non-coding RNAs as drug targets","volume":"16","author":"Matsui","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5306\/wjco.v13.i1.1","article-title":"Update on the treatment of metastatic renal cell carcinoma","volume":"13","author":"Medina Lopez","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cell.2012.05.003","article-title":"Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons","volume":"149","author":"Meyer","year":"2012","journal-title":"Cell"},{"key":"B82","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications - cause and consequence of genome function","volume":"23","author":"Millan-Zambrano","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-020-00736-4","article-title":"Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation","volume":"52","author":"Morgan","year":"2020","journal-title":"Nat. Genet."},{"key":"B84","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.canlet.2011.03.010","article-title":"Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms","volume":"306","author":"Mueller","year":"2011","journal-title":"Cancer Lett."},{"key":"B85","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1073\/pnas.1722330115","article-title":"Modulation of transcriptional burst frequency by histone acetylation","volume":"115","author":"Nicolas","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B86","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cbpa.2016.06.021","article-title":"Advances and challenges in understanding histone demethylase biology","volume":"33","author":"Nowak","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat. Commun."},{"key":"B88","doi-asserted-by":"publisher","first-page":"17824","DOI":"10.1021\/acs.jmedchem.1c00966","article-title":"Installation of pargyline, a LSD1 inhibitor, in the HDAC inhibitory template culminated in the identification of a tractable antiprostate cancer agent","volume":"64","author":"Ojha","year":"2021","journal-title":"J. Med. Chem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","article-title":"Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance","volume":"23","author":"Padeken","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1007\/s12031-022-02051-5","article-title":"STUB1-SMYD2 Axis regulates drug resistance in glioma cells","volume":"72","author":"Pan","year":"2022","journal-title":"J. Mol. Neurosci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-016-0561-z","article-title":"STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer","volume":"15","author":"Pan","year":"2016","journal-title":"Mol. Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2967\/jnumed.120.244459","article-title":"18F-Fluoroestradiol PET imaging in a phase II trial of vorinostat to restore endocrine sensitivity in ER+\/HER2\u2212 metastatic breast cancer","volume":"62","author":"Peterson","year":"2021","journal-title":"J. Nucl. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/bjc.2017.33","article-title":"Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: A multicentre, single-arm phase I\/II clinical trial","volume":"116","author":"Pili","year":"2017","journal-title":"Br. J. Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1158\/0008-5472.CAN-19-0442","article-title":"BRD4 promotes gastric cancer progression and metastasis through acetylation-dependent stabilization of snail","volume":"79","author":"Qin","year":"2019","journal-title":"Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.canlet.2019.04.016","article-title":"HOX transcript antisense RNA (HOTAIR) in cancer","volume":"454","author":"Qu","year":"2019","journal-title":"Cancer Lett."},{"key":"B96","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.tig.2021.06.017","article-title":"There is another: H3K27me3-mediated genomic imprinting","volume":"38","author":"Raas","year":"2022","journal-title":"Trends Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2021.2020164","article-title":"Investigation of intermolecular interactions and binding mechanism of PU139 and PU141 molecules with p300 HAT enzyme via molecular docking, molecular dynamics simulations and binding free energy analysis","volume":"2022","author":"Ramakrishnan","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B98","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(10)70058-9","article-title":"Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: The pelvic radiation and vorinostat (PRAVO) phase 1 study","volume":"11","author":"Ree","year":"2010","journal-title":"Lancet Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdl081","article-title":"Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: Results of a phase II randomized, double-blind, placebo-controlled, multicenter study","volume":"17","author":"Richards","year":"2006","journal-title":"Ann. Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"a018614","DOI":"10.1101\/cshperspect.a018614","article-title":"lncRNAs: linking RNA to chromatin","volume":"6","author":"Rinn","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.celrep.2018.09.082","article-title":"Pan-cancer landscape of aberrant DNA methylation across human tumors","volume":"25","author":"Saghafinia","year":"2018","journal-title":"Cell Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","article-title":"A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas","volume":"58","author":"Sborov","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"B105","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.1021\/jm100217a","article-title":"(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators","volume":"53","author":"Sharma","year":"2010","journal-title":"J. Med. Chem."},{"key":"B106","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccr.2014.01.028","article-title":"Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer","volume":"25","author":"Shi","year":"2014","journal-title":"Cancer Cell"},{"key":"B107","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1756-8722-2-31","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J. Hematol. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B110","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41580-022-00526-2","article-title":"Cellular role of TETs in early embryos","volume":"23","author":"Strzyz","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.celrep.2015.03.037","article-title":"Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains","volume":"11","author":"Stuhlmiller","year":"2015","journal-title":"Cell Rep."},{"key":"B112","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.3892\/ol.2018.9390","article-title":"DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells","volume":"16","author":"Sun","year":"2018","journal-title":"Oncol. Lett."},{"key":"B113","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1021\/acsmedchemlett.5b00124","article-title":"Discovery of A-893, A new cell-active benzoxazinone inhibitor of lysine methyltransferase SMYD2","volume":"6","author":"Sweis","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"B114","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-3-319-43624-1_4","article-title":"Domain structure of the Dnmt1, Dnmt3a, and Dnmt3b DNA methyltransferases","volume":"945","author":"Tajima","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1021\/acs.jmedchem.5b01732","article-title":"Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7\/9 (Set7\/9) that regulates estrogen-dependent transcription","volume":"59","author":"Takemoto","year":"2016","journal-title":"J. Med. Chem."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers13061376","article-title":"Epigenetic treatment of urothelial carcinoma cells sensitizes to cisplatin chemotherapy and PARP inhibitor treatment","volume":"13","author":"Thy","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2174\/156800912800190884","article-title":"An epigenetic approach to pancreatic cancer treatment: The prospective role of histone deacetylase inhibitors","volume":"12","author":"Tinari","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"B118","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.1192002","article-title":"Long noncoding RNA as modular scaffold of histone modification complexes","volume":"329","author":"Tsai","year":"2010","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/s41467-020-18013-7","article-title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer","volume":"11","author":"Vatapalli","year":"2020","journal-title":"Nat. Commun."},{"key":"B120","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ejh.13188","article-title":"Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies","volume":"102","author":"von Tresckow","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3390\/cancers13112799","article-title":"Pharmacological inhibition of CBP\/p300 blocks estrogen receptor alpha (ER\u03b1) function through suppressing enhancer H3K27 acetylation in luminal breast cancer","volume":"13","author":"Waddell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/10428194.2018.1492122","article-title":"Resminostat in patients with relapsed or refractory Hodgkin lymphoma: Results of the phase II SAPHIRE study","volume":"60","author":"Walewski","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B123","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","article-title":"The potential role of RNA N6-methyladenosine in Cancer progression","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12943-020-01256-9","article-title":"Characterization of a novel HDAC\/RXR\/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","article-title":"A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy","volume":"35","author":"Wass","year":"2021","journal-title":"Leukemia"},{"key":"B127","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jconrel.2015.09.023","article-title":"Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target","volume":"220","author":"Waters","year":"2015","journal-title":"J. Control Release"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1002\/ijc.27555","article-title":"Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor","volume":"131","author":"Willmann","year":"2012","journal-title":"Int. J. Cancer"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2011.38.9411","article-title":"Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy","volume":"30","author":"Witta","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.bmc.2008.12.014","article-title":"Bisubstrate inhibitors of the MYST HATs Esa1 and Tip60","volume":"17","author":"Wu","year":"2009","journal-title":"Bioorg Med. Chem."},{"key":"B131","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12935-021-01908-w","article-title":"BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"B132","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1158\/0008-5472.CAN-20-0132","article-title":"FTO inhibition enhances the antitumor effect of temozolomide by targeting MYC-miR-155\/23a cluster-MXI1 feedback circuit in glioma","volume":"80","author":"Xiao","year":"2020","journal-title":"Cancer Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1186\/s12885-019-5852-5","article-title":"Sirtuin1 activator SRT2183 suppresses glioma cell growth involving activation of endoplasmic reticulum stress pathway","volume":"19","author":"Ye","year":"2019","journal-title":"BMC Cancer"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.drudis.2019.08.006","article-title":"DNA methyltransferases: Emerging targets for the discovery of inhibitors as potent anticancer drugs","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B137","doi-asserted-by":"publisher","first-page":"106582","DOI":"10.1016\/j.phrs.2022.106582","article-title":"Epigenetic regulation of autophagy by non-coding RNAs in gastrointestinal tumors: Biological functions and therapeutic perspectives","volume":"187","author":"Zandieh","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/cr.2014.151","article-title":"FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis","volume":"24","author":"Zhao","year":"2014","journal-title":"Cell Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41594-018-0166-x","article-title":"Nucleosome structure and dynamics are coming of age","volume":"26","author":"Zhou","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-020-01216-3","article-title":"Mechanism of RNA modification N6-methyladenosine in human cancer","volume":"19","author":"Zhou","year":"2020","journal-title":"Mol. Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s11427-013-4553-6","article-title":"Function of lncRNAs and approaches to lncRNA-protein interactions","volume":"56","author":"Zhu","year":"2013","journal-title":"Sci. China Life Sci."},{"key":"B143","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00726-011-1004-1","article-title":"Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells","volume":"42","author":"Zhu","year":"2012","journal-title":"Amino Acids"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1085391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T04:43:25Z","timestamp":1672807405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.1085391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":143,"alternative-id":["10.3389\/fgene.2022.1085391"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.1085391","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1085391"}}